Microbot Medical Inc. (NASDAQ:MBOT) Given Consensus Rating of “Hold” by Analysts

Microbot Medical Inc. (NASDAQ:MBOT) has received a consensus rating of “Hold” from the five analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $6.3750.

A number of equities analysts have recently issued reports on MBOT shares. Zacks Research downgraded shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. B. Riley Financial reissued a “buy” rating and set a $4.00 price objective (down from $5.00) on shares of Microbot Medical in a report on Friday, August 14th. HC Wainwright reaffirmed a “buy” rating on shares of Microbot Medical in a report on Wednesday, August 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research report on Wednesday, July 8th. Finally, Loop Capital set a $4.00 price target on Microbot Medical in a research note on Wednesday, June 3rd.

Microbot Medical Price Performance

MBOT opened at $1.44 on Friday. Microbot Medical has a 12 month low of $1.44 and a 12 month high of $4.67. The stock has a market capitalization of $96.72 million, a P/E ratio of -6.00 and a beta of 1.03. The business has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $2.02.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.13 million. Research analysts anticipate that Microbot Medical will post -0.29 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. CTC Alternative Strategies Ltd. purchased a new stake in shares of Microbot Medical in the 1st quarter worth about $28,000. American Century Companies Inc. purchased a new position in Microbot Medical during the 2nd quarter valued at about $32,000. Zacks Investment Management acquired a new position in Microbot Medical during the third quarter worth about $33,000. Man Group plc purchased a new stake in shares of Microbot Medical in the fourth quarter valued at about $35,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Microbot Medical in the third quarter valued at about $37,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.